Cases & Deals

  • Home
  • Practices
  • GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech Corporation

Share

GenScript Biotech Corporation completes US$344.6 million follow-on offering by Legend Biotech Corporation

December 2021

Client(s) GenScript Biotech Corporation

Jones Day represented GenScript Biotech Corporation in connection with its US$344.6 million follow-on offering by its NASDAQ-subsidiary Legend Biotech Corporation. GenScript Biotech Corporation is a well-recognized life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. Its subsidiary Legend Biotech Corporation is a global, clinical-stage biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, it is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.